Charles River Laboratories International, Inc. is a contract research organization that provides drug discovery, non-clinical development, and safety testing services globally. Its revenue is derived from three main segments: Research Models and Services (RMS) (approximately 40%), Discovery and Safety Assessment (DSA) (around 50%), and Manufacturing Solutions (about 10%). The RMS segment focuses on producing rodent research models and related services, while the DSA segment offers early-stage drug discovery and safety assessment services. The Manufacturing segment provides quality control testing and specialized testing for pharmaceuticals and biologics. Factors supporting the company's endurance include its established reputation in the industry and the ongoing demand for drug development services, while potential limitations include regulatory changes and competition from other research organizations.
—
Charles River Laboratories International, Inc. is a contract research organization that provides drug discovery, non-clinical development, and safety testing services globally. Its revenue is derived from three main segments: Research Models and Services (RMS) (approximately 40%), Discovery and Safety Assessment (DSA) (around 50%), and Manufacturing Solutions (about 10%). The RMS segment focuses on producing rodent research models and related services, while the DSA segment offers early-stage drug discovery and safety assessment services. The Manufacturing segment provides quality control testing and specialized testing for pharmaceuticals and biologics. Factors supporting the company's endurance include its established reputation in the industry and the ongoing demand for drug development services, while potential limitations include regulatory changes and competition from other research organizations.
—
Daily adjusted close
Charles River Laboratories International, Inc. is a contract research organization that provides drug discovery, non-clinical development, and safety testing services globally. Its revenue is derived from three main segments: Research Models and Services (RMS) (approximately 40%), Discovery and Safety Assessment (DSA) (around 50%), and Manufacturing Solutions (about 10%). The RMS segment focuses on producing rodent research models and related services, while the DSA segment offers early-stage drug discovery and safety assessment services. The Manufacturing segment provides quality control testing and specialized testing for pharmaceuticals and biologics. Factors supporting the company's endurance include its established reputation in the industry and the ongoing demand for drug development services, while potential limitations include regulatory changes and competition from other research organizations.